James R Berenson, MD
President and CEO – James R. Berenson, M.D., Inc.
Medical & Scientific Director
Institute for Myeloma & Bone Cancer Research (IMBCR)
Chief Executive Officer
Oncotherapeutics
W. Hollywood, CA
Patientpower.comNovember 2007 Hear Dr. Berenson speak on:
Contemporary Issues in Relapsed-Refractory Myeloma
We've been receiving hundreds of questions from myeloma patients. While we can't answer them all, they do tend to cover common ground. We'll address key topics in our next live webcast, the fourth in a series of 7 programs. Join us for our discussion with Dr. James Berenson, Founder, President and CEO of the Institute for Myeloma and Bone Cancer Research. Replay Available here
IONlinkAugust 2006
A Phase I/II Study of Trisenox®, VELCADE® and Ascorbic Acid in Relapsed/Refractory Multiple Myeloma. Read the article...
Oncology TimesAugust 2006
Zoledronic Acid Extends Survival In Lung Cancer & Multiple Myeloma Patients With High Levels of Bone Metabolism. Read the article...
American Cancer SocietyNovember 2005
Safety of Prolonged Therapy with Bortezomib in Relapsed or Refractory Multiple Myeloma Read the article...
Berenson Oncology
9201 Sunset Blvd., Suite 310
West Hollywood, CA 90069
Tel: 310 623.1222
Fax: 310 623.1122